Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: Indication
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Indication

1 evidence topic · 1 source

HARMONi target population

“Patients with EGFR+ Non-squamous NSCLC Who Have Progressed After 3rd-Generation EGFR-TKI (osimertinib)” (opens the source at this quote in a new tab)